publication venue for
- Authorship in reports of clinical practice guidelines: A systematic cross-sectional analysis. 72:e13083-e13083. 2018
- General practitioners’ insight into deprescribing for the multimorbid older individual: a qualitative study. 70:261-276. 2016
- Management of reflux esophagitis: does the choice of proton pump inhibitor matter?. 69:796-801. 2015
- Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. 67:516-526. 2013
- Denosumab: mechanism of action and clinical outcomes. 66:1139-1146. 2012
- Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. 66:457-464. 2012
- Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands - The EXAMINE-AF study. A questionnaire survey. 61:24-31. 2007
- Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain. 59:62-68. 2005
- The application of budesonide/formoterol (Symbicort®) adjustable maintenance dosing to real-life clinical practice. 58:42-46. 2004
- The design of venous thromboembolism prophylaxis trials: Fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. 58:483-493. 2004
- Angiotensin-converting enzyme inhibitors as a new frontier in cardiovascular prevention: Results of the HOPE trial. 7-7. 2001
- Diabetes and the HOPE study: implications for macrovascular and microvascular disease.. 8-12. 2001
- Modifying the natural history of atherosclerosis: the SECURE trial.. 13-18. 2001
- Emerging approaches in the prevention of atherosclerotic cardiovascular diseases.. 94:7-19. 1998
- The global problem of cardiovascular disease.. 94:3-6. 1998
- New antithrombotic strategies: Lessens from clinical trials with glycoprotein IIb/IIIa antagonists and direct thrombin inhibitors 1997
- Pathophysiology and management of patients with acute ischaemic syndromes: Some perspectives 1997